Searchable abstracts of presentations at key conferences in endocrinology

ea0077oc5.2 | Bone and Calcium | SFEBES2021

Gastric inhibitory polypeptide (GIP) reduces human osteoclast activity by suppressing multiple signalling pathways

Hansen Morten S , Soe Kent , Gorvin Caroline M , Frost Morten

Gastric inhibitory polypeptide (GIP) is a post-prandially secreted gut hormone that acts upon the GIP-receptor (GIPR), to stimulate insulin secretion. Animal studies indicate that GIP influences bone remodelling, and in humans, GIP administration decreases levels of bone resorption markers. However, the mechanisms by which GIP influences resorption remain to be elucidated. Therefore, we investigated how GIP (10nM) affects bone cell activity using primary human osteoclasts, hum...

ea0044oc1.6 | Early Career Oral Communications | SFEBES2016

A time controlled β-cell specific mouse model Men1L/L/RIP2-CreER for pancreatic neuroendocrine tumours (NETs)

Vas Nunes Roeland P , Frost Morten , Stevenson Mark , Lines Kate E , Thakker Rajesh V

Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant disorder characterised by occurrence of parathyroid tumours and neuroendocrine tumours (NETs) of the pancreas and pituitary, which is caused by mutations of the MEN1 gene, encoding menin. Mouse models are important in elucidating mechanisms of MEN1 tumourigenesis and treatments, but the current models have limitations. Thus, in conventional heterozygous MEN1 knockout models, tumour d...